Top

World Journal of Surgery

Published in:

01-11-2010

CacyBP/SIP Expression is Involved in the Clinical Progression of Breast Cancer

Authors: Ningju Wang, Qingyong Ma, Yinna Wang, Gang Ma, Huihong Zhai

Published in: World Journal of Surgery | Issue 11/2010

Abstract

Objective

Calcyclin-binding protein or Siah-1-interacting protein (CacyBP/SIP) is a target protein of the S100A6, which is a member of the S100 family. It has been shown that CacyBP/SIP plays important roles in cell cycle progression, differentiation, and carcinogenesis. The purpose of this study was to explore the correlation of CacyBP/SIP expression and clinical significance in breast cancer.

Methods

Immunohistochemistry was performed to detect the CacyBP/SIP expression in 79 pairs of breast cancer tissues and adjacent nontumor tissues. Western blot analysis and semiquantitative RT-PCR were used to measure CacyBP/SIP protein and mRNA levels in three pairs of fresh breast cancer tissues and adjacent nontumor tissues. The clinical data were collected by telephone follow-up for 5 years.

Results

CacyBP/SIP mRNA and protein levels in breast cancer tissues were significantly higher compared with adjacent nontumor tissues. Poor cellular differentiation, lymph node invasion, and clinicopathological staging in breast cancer were associated with CacyBP/SIP expression. Other factors, such as age, menses, and tumor size, were not related to CacyBP/SIP expression. The up-regulation of CacyBP/SIP expression also was shown to increase recurrence and metastasis of breast cancer and to correlate with short overall survival rate.

Conclusions

CacyBP/SIP expression is evident in more advanced clinical progression of breast cancer, and it might be a biomarker for poor prognosis and a potential therapeutic target in breast cancer.

Kim K, Zang R, Choi SC, Ryu SY, Kim JW (2009) Current status of gynecological cancer in China. J Gynecol Oncol 20(2):72–76CrossRefPubMed

Leung GM, Thach TQ, Lam TH, Hedley AJ, Foo W, Fielding R, Yip PS, Lau EM, Wong CM (2002) Trends in breast cancer incidence in Hong Kong between 1973 and 1999: an age-period-cohort analysis. Br J Cancer 87(9):982–988CrossRefPubMed

Yang L, Parkin DM, Ferlay J, Li L, Chen Y (2005) Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 14(1):243–250PubMed

Yang L, Parkin DM, Li L, Chen Y (2003) Time trends in cancer mortality in China: 1987–1999. Int J Cancer 106(5):771–783CrossRefPubMed

Kwong A, Cheung P, Chan S, Lau S (2008) Breast cancer in Chinese women younger than age 40: are they different from their older counterparts? World J Surg 32(12):2554–2561CrossRefPubMed

Olopade OI, Grushko TA, Nanda R, Huo D (2008) Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res 14(24):7988–7999CrossRefPubMed

Tian XS, Cong MH, Zhou WH, Zhu J, Chen YZ, Liu Q (2008) Clinicopathologic and prognostic characteristics of triple-negative breast cancer. Onkologie 31(11):610–614CrossRefPubMed

Anders C, Carey LA (2008) Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 22(11):1233–1239 discussion 1239-1240, 1243

Schnitt SJ (2003) Benign breast disease and breast cancer risk: morphology and beyond. Am J Surg Pathol 27(6):836–841CrossRefPubMed

10.

Filipek A, Wojda U (1996) p30, a novel protein target of mouse calcyclin (S100A6). Biochem J 320(Pt 2):585–587PubMed

11.

Filipek A, Kuznicki J (1998) Molecular cloning and expression of a mouse brain cDNA encoding a novel protein target of calcyclin. J Neurochem 70(5):1793–1798CrossRefPubMed

12.

Matsuzawa S, Li C, Ni CZ, Takayama S, Reed JC, Ely KR (2003) Structural analysis of Siah1 and its interactions with Siah-interacting protein (SIP). J Biol Chem 278(3):1837–1840CrossRefPubMed

13.

Filipek A, Michowski W, Kuznicki J (2008) Involvement of S100A6 (calcyclin) and its binding partners in intracellular signaling pathways. Adv Enzyme Regul 48:225–239CrossRefPubMed

14.

Ning X, Sun S, Hong L, Liang J, Liu L, Han S, Liu Z, Shi Y, Li Y, Gong W et al (2007) Calcyclin-binding protein inhibits proliferation, tumorigenicity, and invasion of gastric cancer. Mol Cancer Res 5(12):1254–1262CrossRefPubMed

15.

Sun S, Ning X, Liu J, Liu L, Chen Y, Han S, Zhang Y, Liang J, Wu K, Fan D (2007) Overexpressed CacyBP/SIP leads to the suppression of growth in renal cell carcinoma. Biochem Biophys Res Commun 356(4):864–871CrossRefPubMed

16.

Chen X, Han G, Zhai H, Zhang F, Wang J, Li X, Huang S, Wang X, Fan D (2008) Expression and clinical significance of CacyBP/SIP in pancreatic cancer. Pancreatology 8(4–5):470–477CrossRefPubMed

17.

Zhai H, Shi Y, Jin H, Li Y, Lu Y, Chen X, Wang J, Ding L, Wang X, Fan D (2008) Expression of calcyclin-binding protein/Siah-1 interacting protein in normal and malignant human tissues: an immunohistochemical survey. J Histochem Cytochem 56(8):765–772CrossRefPubMed

18.

Shimizu M, Saitoh Y, Itoh H (1990) Immunohistochemical staining of Ha-ras oncogene product in normal, benign, and malignant human pancreatic tissues. Hum Pathol 21(6):607–612CrossRefPubMed

19.

Liu J, Stevens J, Rote CA, Yost HJ, Hu Y, Neufeld KL, White RL, Matsunami N (2001) Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell 7(5):927–936CrossRefPubMed

20.

Matsuzawa SI, Reed JC (2001) Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell 7(5):915–926CrossRefPubMed

21.

Shi Y, Hu W, Yin F, Sun L, Liu C, Lan M, Fan D (2004) Regulation of drug sensitivity of gastric cancer cells by human calcyclin-binding protein (CacyBP). Gastric Cancer 7(3):160–166CrossRefPubMed

22.

Yang YJ, Liu WM, Zhou JX, Cao YJ, Li J, Peng S, Wang L, Yuan JG, Duan EK (2006) Expression and hormonal regulation of calcyclin-binding protein (CacyBP) in the mouse uterus during early pregnancy. Life Sci 78(7):753–760CrossRefPubMed

23.

Fukushima T, Zapata JM, Singha NC, Thomas M, Kress CL, Krajewska M, Krajewski S, Ronai Z, Reed JC, Matsuzawa S (2006) Critical function for SIP, a ubiquitin E3 ligase component of the beta-catenin degradation pathway, for thymocyte development and G1 checkpoint. Immunity 24(1):29–39CrossRefPubMed

24.

Zhai H, Shi Y, Yu J, Hong L, Tang H, Wang J, Hu S, Bai F, Fan D (2006) Establishment and characterization of calcyclin binding protein (CacyBP) monoclonal antibody. Hybridoma (Larchmt) 25(2):91–94CrossRef

25.

Salama I, Malone PS, Mihaimeed F, Jones JL (2008) A review of the S100 proteins in cancer. Eur J Surg Oncol 34(4):357–364PubMed

26.

Schafer BW, Heizmann CW (1996) The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 21(4):134–140PubMed

27.

Lee YT, Dimitrova YN, Schneider G, Ridenour WB, Bhattacharya S, Soss SE, Caprioli RM, Filipek A, Chazin WJ (2008) Structure of the S100A6 complex with a fragment from the C-terminal domain of Siah-1 interacting protein: a novel mode for S100 protein target recognition. Biochemistry 47(41):10921–10932CrossRefPubMed

28.

Moog-Lutz C, Bouillet P, Regnier CH, Tomasetto C, Mattei MG, Chenard MP, Anglard P, Rio MC, Basset P (1995) Comparative expression of the psoriasin (S100A7) and S100C genes in breast carcinoma and co-localization to human chromosome 1q21–q22. Int J Cancer 63(2):297–303CrossRefPubMed

29.

Wicki R, Franz C, Scholl FA, Heizmann CW, Schafer BW (1997) Repression of the candidate tumor suppressor gene S100A2 in breast cancer is mediated by site-specific hypermethylation. Cell Calcium 22(4):243–254CrossRefPubMed

30.

Maelandsmo GM, Florenes VA, Mellingsaeter T, Hovig E, Kerbel RS, Fodstad O (1997) Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int J Cancer 74(4):464–469CrossRefPubMed

31.

Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M (2002) Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 110(5):633–641PubMed

32.

Kilanczyk E, Filipek S, Jastrzebska B, Filipek A (2009) CacyBP/SIP binds ERK1/2 and affects transcriptional activity of Elk-1. Biochem Biophys Res Commun 380(1):54–59CrossRefPubMed

Title: CacyBP/SIP Expression is Involved in the Clinical Progression of Breast Cancer
Authors: Ningju Wang
Qingyong Ma
Yinna Wang
Gang Ma
Huihong Zhai
Publication date: 01-11-2010
Publisher: Springer-Verlag
Published in: World Journal of Surgery / Issue 11/2010
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-010-0690-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

CacyBP/SIP Expression is Involved in the Clinical Progression of Breast Cancer

Abstract

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2010

Foley Catheter Enterostomy for Postoperative Bowel Perforation: An Effective Source Control

Ratification of IATSIC/WHO’s Guidelines for Essential Trauma Care Assessment in the South American Region

The Systemic Inflammatory Response Syndrome (SIRS)—Number and Type of Positive Criteria Predict Interventions and Outcomes in Acute Surgical Admissions

In vitro Effectiveness of Garlic (Allium sativum) Extract on Scolices of Hydatid Cyst

Prognostic Value of Body Mass Index on Short-Term and Long-Term Outcome after Resection of Esophageal Cancer

Risk Factors for Litigation Following Major Transectional Bile Duct Injury Sustained at Laparoscopic Cholecystectomy